+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Neurologic Disorders Therapeutics Market by Application and Geography - Global Forecast and Analysis 2019-2023 - Product Image

Neurologic Disorders Therapeutics Market by Application and Geography - Global Forecast and Analysis 2019-2023

  • ID: 4825984
  • Report
  • Region: Global
  • 137 pages
  • TechNavio
UP TO OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Biogen Inc.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Pfizer Inc.
  • MORE
Global Neurologic Disorders Therapeutics Market: About this market

The neurologic disorders therapeutics market analysis considers sales from both CNS and PNS. Our analysis also considers the sales of neurologic disorders therapeutics in Asia, Europe, North America, and ROW. In 2018, the CNS segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as recent drug approvals, the increasing geriatric population will play a significant role in the CNS segment to maintain its market position. Also, our global neurologic disorders therapeutics market report looks at factors such as approval of novel drugs, alliances, and collaborations, and changing lifestyle. However, uncertainties in the advent of neurostimulation devices, the dominance of generics in major neurologic indications, and social stigma associated with neurologic disorders may hamper the growth of the neurologic disorders therapeutics industry over the forecast period.

Global Neurologic Disorders Therapeutics Market: Overview

Approval of novel drugs

The global neurologic disorders therapeutics market is expected to benefit significantly from the recent approvals of various novel drugs for the treatment of major indications. Multiple sclerosis is a widely researched neurological disorder, and several drugs were approved in recent years for the treatment of the indication. Vendors have been conducting studies for the development of disease-modifying drugs for the treatment of the indication, which is expected to cater to the unmet need in the market. This will lead to the expansion of the global neurologic disorders’ therapeutics market at a CAGR of almost 5% during the forecast period.

Advances in the diagnosis of neurogenerative indications

One of the major challenges faced by the global neurological disorders’ therapeutics market is the lack of effective diagnostic processes for neurodegenerative indications. Hence the need for the development of biomarkers for the indication can lead to early diagnosis and help detect the progression of the disease accurately. This development is expected to have a positive impact on the overall market growth.

Competitive Landscape

With the presence of several major players, the global neurologic disorders therapeutics market is fragmented. This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading neurologic disorders therapeutics manufacturers, that include Biogen Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., Novartis AG, Pfizer Inc.

Also, the neurologic disorders therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Biogen Inc.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Pfizer Inc.
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY APPLICATION
  • Market segmentation by application
  • Comparison by application
  • CNS - Market size and forecast 2018-2023
  • PNS - Market size and forecast 2018-2023
  • Market opportunity by application
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS
  • Advent of regenerative medicines
  • Advances in diagnosis of neurodegenerative indications
  • Drug reformulations
PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Biogen Inc.
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services Inc.
  • Novartis AG
  • Pfizer Inc.
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List of Exhibits:
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ billions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Application - Market share 2018-2023 (%)
Exhibit 19: Comparison by application
Exhibit 20: CNS - Market size and forecast 2018-2023 ($ billions)
Exhibit 21: CNS - Year-over-year growth 2019-2023 (%)
Exhibit 22: PNS - Market size and forecast 2018-2023 ($ billions)
Exhibit 23: PNS - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by application
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America - Market size and forecast 2018-2023 ($ billions)
Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in North America
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ billions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in Europe
Exhibit 34: Asia - Market size and forecast 2018-2023 ($ billions)
Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Asia
Exhibit 37: ROW - Market size and forecast 2018-2023 ($ billions)
Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in ROW
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: Impact of drivers and challenges
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: Biogen Inc. - Vendor overview
Exhibit 49: Biogen Inc. - Business segments
Exhibit 50: Biogen Inc. - Organizational developments
Exhibit 51: Biogen Inc. - Geographic focus
Exhibit 52: Biogen Inc. - Key offerings
Exhibit 53: Biogen Inc. - Key customers
Exhibit 54: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 55: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 56: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 57: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 58: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 59: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 60: F. Hoffmann-La Roche Ltd. - Key customers
Exhibit 61: Johnson & Johnson Services Inc. - Vendor overview
Exhibit 62: Johnson & Johnson Services Inc. - Business segments
Exhibit 63: Johnson & Johnson Services Inc. - Organizational developments
Exhibit 64: Johnson & Johnson Services Inc. - Geographic focus
Exhibit 65: Johnson & Johnson Services Inc. - Segment focus
Exhibit 66: Johnson & Johnson Services Inc. - Key offerings
Exhibit 67: Johnson & Johnson Services Inc. - Key customers
Exhibit 68: Novartis AG - Vendor overview
Exhibit 69: Novartis AG - Business segments
Exhibit 70: Novartis AG - Organizational developments
Exhibit 71: Novartis AG - Geographic focus
Exhibit 72: Novartis AG - Segment focus
Exhibit 73: Novartis AG - Key offerings
Exhibit 74: Novartis AG - Key customers
Exhibit 75: Pfizer Inc. - Vendor overview
Exhibit 76: Pfizer Inc. - Business segments
Exhibit 77: Pfizer Inc. - Organizational developments
Exhibit 78: Pfizer Inc. - Geographic focus
Exhibit 79: Pfizer Inc. - Segment focus
Exhibit 80: Pfizer Inc. - Key offerings
Exhibit 81: Pfizer Inc. - Key customers
Exhibit 82: Validation techniques employed for market sizing
Exhibit 83: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Biogen Inc.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Pfizer Inc.
  • MORE
The following companies are recognised as the key players in the global neurologic disorders therapeutics market: Biogen Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., Novartis AG, Pfizer Inc.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the advances in the diagnosis of neurogenerative indications.”

According to the report, one of the major drivers for this market is the approval of novel drugs.

Further, the report states that one of the major factors hindering the growth of this market is the dominance of generics in major neurologic indications.

The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Biogen Inc.
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services Inc.
  • Novartis AG
  • Pfizer Inc.
Note: Product cover images may vary from those shown
Adroll
adroll